Foghorn Therapeutics (FHTX) Reiterated at Buy by Stifel After AACR'26 Presentation
Tweet Send to a Friend
Stifel analyst Laura Prendergast reiterated a Buy rating and $12.00 price target on Foghorn Therapeutics (NASDAQ: FHTX).The analyst commented, "At ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


